Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC
Status:
RECRUITING
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
Based on the FRECO-2 study, Fruquintinib has become one of the standard third-line treatments for advanced colorectal cancer; however, its objective response rate (ORR) remains low. Our previous studies have shown that the combination of raltitrexed and S-1 -/+ bevacizumab is effective and provides a significant survival benefit in patients with metastatic colorectal cancer (mCRC) who are refractory to standard treatments. This study aims to evaluate the efficacy and safety of combining Fruquintinib with S-1 and raltitrexed in these patients.
Phase:
PHASE2
Details
Lead Sponsor:
Meng Qiu
Collaborator:
Beijing Xisike Clinical Oncology Research Foundation
Treatments:
gimeracil HMPL-013 potassium oxonate raltitrexed S 1 (combination) Tegafur